

5

BETA-LACTAMASE INHIBITOR PRODRUG

BACKGROUND OF THE INVENTION

Beta-lactam antibiotics, which generally are penicillins and cephalosporins, have been widely used in the treatment of infections, primarily bacterial, in mammals such as man. Certain micro-organisms are believed to be resistant to these antibiotics because they produce various beta-lactamase enzymes which attack the beta-lactam ring of the antibiotic thereby rendering the drug ineffective.

In U.S. Patent No. 4,287,181, Kellogg disclosed that various 6 β -hydroxyalkylpenicillanic acids, including 6- β -hydroxymethylpenicillanic acid sulfone which is the beta-lactamase inhibitor used in the present invention, are potent beta-lactamase inhibitors. U.K. Patent Application GB2053220A, Metzger *et al.* and U.K. Patent Application GB2076812, by Schneider *et al.*, likewise disclosed that 6- β -hydroxymethyl-penicillanic acid sulfone is a beta-lactamase inhibitor. However, the beta-lactamase inhibitor 6- β -hydroxymethyl-penicillanic acid sulfone is very poorly absorbed *in vivo* in rodents during preclinical studies when administered orally.

Kellogg, Metzger *et al.* and Schneider *et al.* also disclosed ester prodrugs of 6- β -hydroxymethyl-penicillanic acid sulfone, which readily hydrolyze *in vivo*, during preclinical studies, and which demonstrated better absorption in rodents than did the free acid.

However, many of these ester prodrugs could only be synthesized as oils or as solids that had low melting

EXPRESS MAIL NO. EV272782228 US

5 points whose usefulness in pharmaceutical formulations is more limited than would be a solid prodrug with a melting point suitable for tableting, milling or purification.

Furthermore, these ester prodrugs were typically
10 not highly absorbed when orally administered. Thus, higher drug dosages would be required to be administered orally, to obtain a therapeutically effective plasma level of the beta-lactamase inhibitor 6- β -hydroxymethylpenicillanic acid sulfone, than would be required
15 for a more highly absorbed prodrug. In addition, oral administration of the less absorbed prodrugs may result in an increase in the incidence and severity of diarrhea experienced by the recipient as the unabsorbed prodrug may hydrolyze in the gastro-intestinal tract, to form
20 the active drug, and, with any residual amoxicillin, selectively kill essential components of the normal microbial flora. Further, it is desirable that the process, for producing the desired prodrug, be relatively inexpensive.


25 Therefore, there is a need for a crystalline prodrug of the beta-lactamase inhibitor 6- β -hydroxymethylpenicillanic acid sulfone which has a high oral bioavailability, and more preferably is crystalline with a suitable melting point.

30


SUMMARY OF THE INVENTION

The present invention relates to prodrugs of 6- β -hydroxymethylpenicillanic acid sulfone (also named 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-

5 (hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide
(2S,5R,6R)) having the structure



10 and solvates thereof, wherein R is H or methyl. The
prodrugs of the present invention include 4-thia-1-
azabicyclo[3.2.0] heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)-
methyl ester, 4,4-dioxide (2S,5R,6R);
15 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)-
ethyl ester, 4,4-dioxide (2S,5R,6R); 4-thia-1-
azabicyclo[3.2.0] heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-
20 (benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R); and 4-
thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1S)-1-
(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R). The
preferred prodrug of the present invention is 4-thia-1-
25 azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-
(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), which
has the structure



5

or a solvate thereof.

The present invention also relates to pharmaceutical compositions comprising a prodrug of the present invention or a solvate thereof, an optional
 10 beta-lactam antibiotic, and a pharmaceutically acceptable excipient. Preferably, the beta-lactam antibiotic is amoxicillin. It is also preferred that the prodrug, used in the pharmaceutical composition, is 4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid, 6-
 15 (hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R) or a solvate thereof. It is more preferred that the pharmaceutical composition comprises 4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid, 6-(hydroxymethyl)-
 20 3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), or a solvate thereof, amoxicillin and a pharmaceutically acceptable excipient.

The present invention further relates to a method for increasing the therapeutic effectiveness of a beta-
 25 lactam antibiotic in a mammal comprising administering to said mammal an effective amount of a beta-lactam antibiotic and an effectiveness-increasing amount of a prodrug of the present invention, or a solvate thereof. Preferably, the beta-lactam antibiotic is amoxicillin.
 30 It is also preferred that the prodrug used is 4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid, 6-

5 (hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R) or a solvate thereof. It is more preferred that the prodrug is 4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-
10 (benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), or a solvate thereof, and the beta-lactam antibiotic is amoxicillin. It is further preferred that the mammal is a human.

The present invention additionally relates to the
15 treatment of a bacterial infection in a mammal by administering a therapeutically effective amount of a pharmaceutical composition of the present invention to a mammal in need thereof. Preferably, this pharmaceutical composition further comprises a beta-lactam antibiotic.
20 More preferably, the beta-lactam antibiotic is amoxicillin. It is also preferred that the prodrug used is 4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R) or a
25 solvate thereof. It is more preferred that the prodrug is 4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), or a solvate thereof, and the beta-lactam antibiotic is
30 amoxicillin. It is further preferred that the mammal is a human.

5 DETAILED DESCRIPTION

The terms used to describe the present invention have the following meanings herein.

The term "a" means at least one. Thus, for example, the phrase "a pharmaceutically acceptable
10 excipient" means at least one pharmaceutically acceptable excipient.

The term "effective amount" means the amount of beta-lactam antibiotic which, when administered either alone, or in combination with a prodrug of the present
15 invention, prevents the onset of, alleviates the symptoms of, stops the progression of, or eliminates a bacterial infection in a mammal.

The term "effectiveness-increasing amount" means that amount of prodrug which, when administered to a
20 mammal and which subsequently hydrolyzes *in vivo* to form the beta-lactamase inhibitor of the present invention, increases the therapeutic effectiveness of a co-administered beta-lactam antibiotic.

The term "mammal" is an individual animal that is a
25 member of the taxonomic class Mammalia. The class Mammalia includes, for example, humans, monkeys, chimpanzees, gorillas, cattle, swine, horses, sheep, dogs, cats, mice and rats.

In the present invention, the preferred mammal is a
30 human, male or female.

The term excipient, as used herein, means any component of a pharmaceutical formulation other than the prodrug or optional beta-lactamase antibiotic.

The term "pharmaceutically acceptable excipient"
35 means that said excipient must be compatible with other

5 ingredients of the composition, and not deleterious to the recipient thereof. Pharmaceutical compositions of the present invention are prepared by procedures known in the art using well known and readily available ingredients.

10 The prodrugs of the present invention include 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)-methyl ester, 4,4-dioxide (2S,5R,6R) which is described in Example 3, and 4-thia-1-azabicyclo[3.2.0]heptane-2-
15 carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R) which is described in Example 4.

The prodrugs of the present invention, as further described in Example 9, are stable in the upper GI tract
20 but, after absorption, readily hydrolyze *in vivo* to form 6- β -hydroxymethylpenicillanic acid sulfone (hereinafter know as "6- β -HMPAS") which is a beta-lactamase inhibitor that increases the effectiveness of beta-lactam antibiotics against beta-lactamase-producing bacteria.
25 This beta-lactamase inhibition generally preserves the antibacterial potency of a co-administered beta-lactam antibiotic against beta-lactamase (+) strains.

As the prodrugs of the present invention hydrolyze *in vivo* and form the free acid beta-lactamase inhibitor
30 6- β -HMPAS, these prodrugs are useful in that, when administered to a mammal, the effectiveness of a co-administered beta-lactam antibiotic against beta-lactamase producing bacteria will be enhanced.

Prodrugs of this invention may be used, in
35 combination therapy with beta-lactam antibiotics, to

5 treat infections of, for example, the respiratory tract,
the urinary tract and soft tissues in humans.

Compositions of this invention may also be used to treat
infections in other mammals, such as mastitis in cattle.

Bacterial infections amenable to treatment by the
10 prodrug, pharmaceutical composition and method of the
present invention include, but are not limited to, upper
respiratory diseases including community acquired
pneumoniae (CAP), acute exacerbations of chronic
bronchitis (AECB) and acute bacterial sinusitis (ABS),
15 caused by respiratory pathogens, such as *Haemophilus*
influenzae and *Moraxella catarrhalis* including
antibiotic resistant isolates.

Further, bacterial infections amenable to
treatment, by pharmaceutical compositions of the
20 present invention which contain an antibiotic, include,
but are not limited to, pediatric otitis media,
sinusitis, pneumonia and acute exacerbations of
bronchitis in adults caused by *H. influenzae* or
Streptococcus pneumoniae, including Drug Resistant *S.*
25 *pneumoniae* (DRSP) such as Penicillin Resistant *S.*
pneumoniae.

Additional, bacterial infections amenable to
treatment, by pharmaceutical compositions of the
present invention which contain an antibiotic, include,
30 but are not limited to, soft tissue infections caused by
E. Coli, *Klebsiella pneumoniae*, *Enterobacter spp.* and
all other members of the family *Enterobacteriaceae*.

Other infections amenable to treatment, by
pharmaceutical compositions of the present invention
35 which contain an antibiotic, include, but are not

5 limited to, those caused by beta-lactamase producing
methicillin susceptible *staphylococci* and beta-lactamase
producing anaerobes.

As the prodrugs of the present invention contain
more than one chiral center, they exist in different
10 optically active diastereomeric forms. More
specifically, the preferred prodrugs of the present
invention contain a chiral center at the 1-ethyl
location. The present invention includes both 1R and 1S
diastereomers of 4-thia-1-azabicyclo[3.2.0]heptane-2-
15 carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -
1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), and
also includes, and mixtures of these diastereomers, such
as racemic mixtures. These diastereomeric forms, a
mixture thereof, and their respective syntheses are
20 further described herein in the following Examples 4-6.

Even more preferably, the prodrug of the present
invention comprises the 1R diastereomer of 4-thia-1-
azabicyclo[3.2.0]-heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)ethyl
25 ester, 4,4-dioxide (2S,5R,6R) as is described in Example
5.

The prodrugs of the present invention may exhibit
polymorphism. Polymorphs of prodrugs form part of this
invention and may be prepared by crystallization of a
30 prodrug of the present invention under different
conditions. For example, using different solvents or
different solvent mixtures for recrystallization;
crystallization at different temperatures; various modes
of cooling ranging from very fast to very slow cooling
35 during crystallization. Polymorphs may also be obtained

5 by heating or melting a prodrug followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe nmr spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or other such techniques.

10 The prodrugs of the present invention may also exist in the form of solvates, for example, hydrates, ethanolate, n-propanolate, iso-propanolate, 1-butanolate, 2-butanolate and solvates of other physiologically acceptable solvents, such as the Class 3
15 solvents described in the International Conference on Harmonization (ICH), Guidance for Industry, Q3C Impurities: Residual Solvents (1997). The present invention includes each solvate and mixtures thereof.

For a prodrug, the minimum amount of prodrug
20 administered is that amount which will increase the effectiveness of a co-administered beta-lactam antibiotic. The maximum amount of prodrug administered is that amount, which either alone or in combination with the beta-lactam antibiotic, is toxicologically
25 acceptable.

Typically, for adults and children weighing at least 40 kg, the daily dosage amount of prodrug is between about 200 mg to about 1 g or more. For children weighing less than 40 kg, the daily dosage amount of
30 prodrug is between about 7 mg/kg/day to about 20 mg/kg/day or more. However, these figures are illustrative only, and, in some cases, it may be necessary to use dosages outside these limits.

5 A daily dosage of the prodrug of the present invention can be administered from 1 to 4 times daily in equal doses.

 In the treatment of a bacterial infection, a prodrug of the present invention is co-administered with
10 a beta-lactam antibiotic. The prodrug and the beta-lactam antibiotic may be administered concurrently or sequentially. Further, the prodrug and antibiotic may be contained in separate pharmaceutical compositions or in a single pharmaceutical composition.

15 Typical beta-lactam antibiotics, with which the prodrug of the present invention is co-administered, are beta-lactam antibiotics which are sensitive to enzymatic degradation and inactivation by various beta-lactamase enzymes. Examples of such beta-lactamase sensitive
20 antibiotics include, but are not limited to, penicillins such as natural penicillins, amoxicillin and ampicillin; cephalosporins such as cefadroxil, cefazolin, cephalixin, cephalothin, cephapirin, cephradine, cefaclor, cefamandole, cefoicid, ceforanide, cefprozil,
25 cefuroxime, cefdinir, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone and cefepime; and monobactams such as aztreonam.

 Typically, when contained together in a
30 pharmaceutical composition, the weight ratio of beta-lactam antibiotic to prodrug is between about 15:1 to about 1:1.

 Preferably, a prodrug of the present invention is co-administered with amoxicillin. More preferably,
35 amoxicillin is co-administered with the prodrug 4-thia-

5 1-azabicyclo[3.2.0]-heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-
(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R).

The term "amoxicillin" as used herein shall mean
amoxicillin or an alkaline salt, or hydrate thereof such
10 as, in particular, amoxicillin trihydrate or
(crystallized) sodium amoxicillin. Unless otherwise
indicated, weights of amoxicillin refer to the
equivalent weight of the corresponding free acid. In
addition, it will be appreciated that in practice,
15 weights of amoxicillin to be incorporated into a
formulation will be further adjusted, in accord with
conventional practice, to take account of the potency of
the amoxicillin.

Typically, an effective amount of amoxicillin, for
20 adults and children weighing at least 40 kg, is a daily
dosage level of about 250 mg to about 5 g. For children
weighing less than 40 kg, an effectiveness-increasing
amount of amoxicillin is a daily dosage level of about
20 mg/kg/day to about 150 mg/kg/day. However, these
25 figures are illustrative only, and, in some cases, it
may be necessary to use dosages outside these limits.

A daily dosage of amoxicillin can be administered
from 1 to 4 times daily in equal doses in the form of
immediate, modified or delayed (or slow) release
30 compositions. Formulations of immediate, modified and
delayed (slow) release pharmaceutical compositions
containing amoxicillin, which are suitable for the
pharmaceutical composition of the present invention, and
the preparation thereof, are described in United States
35 Patent Nos. 4,537,887, issued to Rooke et al.,

5 6,051,255, issued to Conley et al., 6,218,380, issued to
Cole et al., 6,051,255, issued to Conley et al.; United
States Patent Application Serial Number 09/911,905, by
Conley et al.; and International Application Number
PCT/IB01/01899, by Conley et al. The teachings of U.S.
10 Patent Nos. 4,537,887, 6,051,255, 6,218,380, 6,051,255,
USSN 09/911,905 and International Application Number
PCT/IB01/01899 regarding immediate, modified and delayed
release amoxicillin formulations are incorporated herein
by reference.

15 In these compositions, the exact amount of prodrug
and amoxicillin will depend to some extent on the micro-
organism which is being treated.

As will be appreciated by one skilled in the art,
some of the beta-lactam compounds are effective when
20 administered orally or parenterally, while others are
effective only when administered parenterally. When a
prodrug of the present invention is combined with a
parenterally administered beta-lactam antibiotic, a
pharmaceutical suitable for which is effective only on
25 parenteral administration, a combination formulation
suitable for parenteral use will be employed. When the
prodrug is to be combined with a beta-lactam antibiotic
which is effective orally or parenterally, combinations
suitable for either oral or parenteral administration
30 can be prepared. Additionally, it is possible to
administer preparations of the prodrug orally, while
administering a further beta-lactam antibiotic
parenterally; and it is also possible to administer
preparations of the prodrug parenterally, while
35 administering the further beta-lactam antibiotic orally.

5 A pharmaceutical composition, of the present invention, comprises a prodrug of the present invention and a pharmaceutically acceptable excipient.

 Optionally, the pharmaceutical composition further comprises a beta-lactam antibiotic. It is preferred
10 that the antibiotic is amoxicillin. It is also preferred that the prodrug is 4-thia-1-azabicyclo-[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R). It is more preferred that the
15 pharmaceutical composition comprises 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), amoxicillin and a pharmaceutically acceptable excipient.

20 Typically, excipients, are as known in the art, and include, but are not limited to binders, fillers and extenders, carriers or vehicles, diluents, disintegrants, lubricants, glidants, stabilizers, buffers, bulking or thickening agents, emulsifiers,
25 suspending agents, flavors, sweeteners, and pigments.

 Examples of excipients that are suitable for such pharmaceutical compositions include: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl
30 cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as agar agar, calcium carbonate, and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption
35 accelerators such as quaternary ammonium compounds;

5 surface active agents such as cetyl alcohol, glycerol
monostearate; adsorptive carriers such as kaolin and
bentonite; and lubricants such as talc, calcium and
magnesium stearate and solid polyethylene glycols. The
formulations can additionally include: lubricating
10 agents such as talc, magnesium stearate, and mineral
oil; wetting agents; emulsifying and suspending agents;
preserving agents such as methyl- and
propylhydroxybenzoates; sweetening agents; and flavoring
agents.

15 Suitable examples of methods of preparing
pharmaceutical compositions are provided in Remington's
Pharmaceutical Sciences, Mack Publishing Company,
Easton, Pa., 18th Edition (1990).

In preparing a pharmaceutical composition of the
20 present invention, the prodrug, and optional beta-lactam
antibiotic, are usually mixed with an excipient, diluted
by an excipient or enclosed within a carrier that can be
in the form of a capsule, sachet, or other container.
When the excipient serves as a diluent, it can be a
25 solid, semi-solid, or liquid material that acts as a
vehicle, carrier or medium for the active ingredient.

The pharmaceutical composition can be administered
orally or parenterally, i.e. intramuscularly,
subcutaneously, intravenously or intraperitoneally. The
30 carrier is chosen on the basis of the intended mode of
administration. For example, when considering the oral
mode of administration, a pharmaceutical composition of
this invention can be used in the form of tablets
including chewable tablets, capsules, lozenges, troches,
35 powders, syrups, elixirs, aqueous solutions and

5 suspensions, and the like, in accordance with standard pharmaceutical practice. The proportional ratio of active ingredient to carrier will naturally depend on the chemical nature, solubility and stability of the active ingredients, as well as the dosage contemplated.

10 However, pharmaceutical compositions containing a beta-lactam antibiotic and a prodrug of the present invention will preferably contain from about 20% to about 95% of active ingredients. In the case of tablets for oral use, carriers which are commonly used include, for example,

15 lactose, sodium citrate and salts of phosphoric acid. Various disintegrants such as starch, and lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc, are commonly used in tablets. For oral administration in capsule form, useful diluents include,

20 for example, are lactose and high molecular weight polyethylene glycols. When aqueous solutions or suspensions are required for oral use, the active ingredient may be combined with emulsifying and suspending agents. If desired, certain sweetening and/or

25 flavoring agents can be added. For parenteral administration, sterile solutions of the active ingredients are usually prepared, and the pH of the solutions is suitably adjusted and buffered. For intravenous use, the total concentration of solutes

30 should be controlled to render the preparation isotonic.

The formulations of the invention may be made up into solid dosage forms for oral administration by a method conventional to the art of pharmaceutical technology, e.g. tablets or powder or granular products

35 for reconstitution into a suspension or solution.

5 Suitable ingredients and suitable methods for
making such tablets are disclosed in, for example,
International Applications WO 92/19227 and WO 95/28927
the teachings of which, regarding tablet ingredients and
methods for making tablets, are incorporated herein by
10 reference. Powder or granular formulations, such as
pediatric suspension formulations, may be manufactured
using techniques which are generally conventional in the
field of manufacture of pharmaceutical formulations and
in the manufacture of dry formulations for
15 reconstitution into such suspensions. For example a
suitable technique is that of mixing dry powdered or
granulated ingredients for loading into a suitable
container.

For pediatric dosing, the formulations of the
20 invention are preferably made up into a sweet flavored
aqueous syrup formulation of generally conventional
formulation (except for its novel amoxicillin:prodrug
ratio and intended use) containing a suitable weight of
the amoxicillin and prodrug in a unit dose volume, e.g.
25 5 ml or 2.5 ml preferably as a syrup. A pediatric
formulation may therefore comprise a bulk of a solution
or suspension, e.g. a syrup, or granules or powder which
can be made up into such a solution or suspension, at a
concentration of solution or suspension which contains
30 such a dose in such a volume. Suitable such formulations
are described in International application no PCT
EP96/01881 (SmithKline Beecham). The formulation of this
invention will normally, in addition to its active
materials amoxicillin and prodrug, also include
35 excipients which are standard in the field of

5 formulations for oral dosing and used in generally
standard proportions, and at generally standard particle
sizes and grades etc.

In the case of pediatric oral suspensions, these
excipients may comprise suspending aids, glidants (to
10 aid filling), diluents, bulking agent, flavors,
sweeteners, and stabilizers.

Suitable excipients for use include, for example,
xanthan gum (suspension aid), colloidal silica
(glidant), succinic acid (stabilizer), aspartame
15 (sweetener), hydroxypropylmethylcellulose (suspension
aid) and silicon dioxide (diluent for prodrug and
bulking agent). Flavors may comprise common flavors such
as bubble gum, orange, banana, raspberry, grape and
golden syrup, or mixtures thereof, to suit local
20 requirements.

The pharmaceutical composition of the present
invention may, for example, be provided in solid unit
dose forms embodying suitable quantities for the
administration of such a daily dose. For example a unit
25 dosage form may be tablets, or sachets containing
granules or powders for reconstitution, one or two of
which are to be taken 1-4 times daily. Alternatively a
unit dose may be provided as a bulk of solid or solution
or suspension, e.g. as a syrup for pediatric
30 administration, together with a suitable measuring
device of known type to facilitate administration of a
suitable unit dose quantity of the formulation. A
suitable unit dose quantity is one which enables the
administration of the above-mentioned daily dosage
35 quantity divided 1-4 doses.


5 Yet another embodiment of this invention is a kit,
for achieving an antibacterial therapeutic effect in a
mammal, comprising (1) a pharmaceutical composition,
which comprises a prodrug of the present invention and,
optionally, a beta-lactam antibiotic, and (2) directions
10 for the administration of the pharmaceutical composition
in a manner to achieve the desired therapeutic effect.

The present invention will be further illustrated
by means of the following examples. It is to be
understood, however, that the invention is not meant to
15 be limited to the details described therein.

Example 1

Preparation and Enantiomeric Separation of (R/S) Benzoic acid 1-chloro-ethyl ester

20




(R/S)-Benzoic acid 1-chloro-ethyl ester, shown
25 above, was prepared as follows.

To a stirred solution of 122 g (862 mmol.) benzoyl
chloride (Aldrich), under a nitrogen atmosphere in a 3-
neck round bottom flask, was added 2.35 g (17.2 mmol.)
anhydrous zinc chloride (Aldrich). The reaction mixture
30 was stirred for 15 minutes at room temperature and then
cooled to -15 °C using an ethylene glycol/ CO₂ bath. To
this mixture was added slowly 37.9 g (862 mmol.)

5 acetaldehyde (Aldrich) while maintaining an internal
 temperature below 0 °C. After addition was completed,
 the reaction mixture was allowed to warm to room
 temperature. 400 mL water and 400 mL CH₂Cl₂ were added
 and then the layers were separated. The organic layer
 10 was separated and washed with saturated NaHCO₃, water,
 brine, dried over MgSO₄ filtered and concentrated in
 vacuo. Chromatography on silica gel eluting with 1.75 %
 ethyl acetate/ 98.25 % hexanes afforded 55.4 g of a
 yellow oil. ¹H-NMR (CDCl₃, 400 MHz): 8.08 (d, 2H,
 15 J=7.5Hz), 7.61 (t, 1H, J=7.5Hz), 7.47 (t, 2H, J=7.5Hz),
 6.80 (q, 1H, J=6Hz), 1.93 (d, 3H, J=6Hz).

(R)-Benzoic acid 1-chloro-ethyl ester, shown below,
 was isolated by the chiral separation of (+/-)-benzoic
 acid 1-chloro-ethyl ester using a 10 cm by 50 cm
 20 Chiralcel OJ column eluting with heptane/IPA (98/2) and
 with a flow rate of 250 mL/min. The enantiomer
 collected eluted second with an analytical purity
 retention time of 7.123 min.




25

¹H-NMR (CDCl₃, 400MHz): 8.08 (d, 2H, J=7.5Hz), 7.61 (t,
 1H, J=7.5Hz), 7.47 (t, 2H, J=7.5Hz), 6.80 (q, 1H,
 J=6Hz), 1.93 (d, 3H, J=6Hz). [α_d] = -140° (C+0.0315,
 30 CHCl₃).

(S)-Benzoic acid 1-chloro-ethyl ester, shown below,
 was isolated by the chiral separation of (+/-)-benzoic

5 acid 1-chloro-ethyl ester using a 10 cm by 50 cm
Chiralcel OJ column eluting with heptane/IPA (98/2) and
with a flow rate of 250 mL/min. The enantiomer
collected eluted first with an analytical purity
retention time of 5.807 min.


10



$^1\text{H-NMR}$ (CDCl_3 , 400MHz): 8.08 (d, 2H, $J=7.5\text{Hz}$), 7.61 (t, 1H, $J=7.5\text{Hz}$), 7.47 (t, 2H, $J=7.5\text{Hz}$), 6.80 (q, 1H, $J=6\text{Hz}$), 1.93 (d, 3H, $J=6\text{Hz}$). $[\alpha]_D = +130^\circ$ ($C+0.0345$, CHCl_3).

Example 2

20 Preparation of 4-Thia-1-azabicyclo [3.2.0]heptane-2-
carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-
,4,4-dioxide, monosodium salt, (2S,5R,6R)




25 4-Thia-1-azabicyclo [3,2,0]heptane-2-carboxylic
acid,
6-(hydroxymethyl)-3,3-dimethyl-7-oxo-,4,4-dioxide,
monosodium salt, (2S,5R,6R), shown above, (hereinafter

5 "Na-HMPAS") was prepared by the following four-step process.

Step 1 - Preparation of sodium 6,6-dibromopenicillanate
sulfone


10



Ethyl acetate (15.8 L) was added to 6,6-dibromopenicil-lanic acid sulfone (2500 g) and heated to 50 °C. Sodium ethyl hexanoate (1044 g) and ethyl acetate (5.0 L) were stirred to form a solution then added to the 6,6-dibromopenicillanic acid sulfone solution over a 60 minute period. The reaction mixture was allowed to cool to ambient temperature and the resulting solids granulated for a period of 1 hour. The product was collected by filtration and washed with ethyl acetate to give 2197 g (83%) of the sodium 6,6-dibromo-penicillanate sulfone. M.P. 186-187 °C. ¹HNMR (D₂O) δ 1.30 (s, 3H), 1.45 (s, 3H), 4.29 (s, 1H), 5.54 (s, 1H).


25

5 Step 2 - Preparation of benzyl 6,6-dibromopenicillanate
 sulfone



10 Dimethylformamide (5.7 L) and the sodium 6,6-
 dibromopenicillanate sulfone (3820 g) were combined and
 the mixture was stirred for a few minutes until all of
 the solids dissolved. To this mixture benzyl bromide
 (1400 g) was added over a 1 hour period. The reaction
 15 mixture was then stirred overnight at ambient
 temperature. Water (4.5 L) and ethyl acetate (15.0 L)
 were added to quench the reaction. The aqueous phase
 was washed with ethyl acetate (2 x 600 mL) and the
 combined organic phases were washed sequentially with a
 20 saturated aqueous sodium bicarbonate solution (2 x 1 L)
 and an aqueous sodium chloride solution (2 x 1 L). The
 organic layer was dried over magnesium sulfate and
 concentrated to give 3566 g (90%) of the desired benzyl
 6,6-dibromopenicillanate sulfone as crystals. M.P.
 25 146-147 °C. ¹HNMR (CDCl₃) δ 1.2 (s, 3H), 1.5 (s, 3H),
 4.5 (s, 1H), 4.9 (s, 1H), 5.16 (d, 1H, *J* = 12 Hz), 5.29
 (d, 1H, *J* = 12 Hz), 7.35-7.40 (m, 5H).

5 Step 3 - Preparation of benzyl 6- β -hydroxymethyl-6- α -
 bromopenicillanate sulfone



10 In a round bottom flask, paraformaldehyde was
 heated under a nitrogen sweep to 160-180 °C to express
 excess water. In a separate round bottom flask
 tetrahydrofuran (8.0 L) and benzyl 6,6-
 dibromopenicillanate sulfone (1000 g) were combined and
 15 stirred until all of the solids had dissolved. The
 solution was cooled to -78 °C and 3M methylmagnesium
 chloride in THF (720 mL) was added slowly to the
 solution while maintaining the temperature less than -70
 °C. The reaction mixture was stirred for 1 hour. At
 20 this time, formaldehyde gas expressed from the first
 round bottom flask was blown over the surface of the
 chilled reaction mixture using a stream of nitrogen.
 This formaldehyde gas was expressed over the reaction
 mixture for approximately 6 hours while maintaining
 25 cooling and vigorous stirring of the chill reaction
 flask. Upon reaction completion determined by TLC
 (80:20 hexanes:ethyl acetate), the reaction was quenched
 at -78 °C with a solution of acetic acid (132 mL) in THF
 (400 ML). The reaction mixture was allowed to warm to
 30 ambient temperature then the reaction mixture was
 filtered through Supercel. The filtrate was

5 concentrated to an oil (~1000 g). The oil was then transferred to a large reaction vessel and ethyl acetate (5.0 L)/water (2.5 L) added. The mixture was stirred, then separated. The aqueous layer was washed with ethyl acetate (2 x 500 mL). The combined organic layers were
 10 sequentially washed with 1N hydrochloric acid (3.0 L), water (3 x 3.0 L), and saturated aqueous sodium chloride solution (3 x 3.0 L). The organic layer was dried with magnesium sulfate, filtered through Supercel®, a calcined filter aid (Celite Corporation, Lompoc, CA),
 15 concentrated and stored in a refrigerator. The resulting oil was chromatographed through silica gel (1 Kg per 500 g of product oil), and eluted with 9:1 hexane/ ethyl acetate (20.0 L) to remove impurities then 4:1 hexane/ ethyl acetate (4.0-8.0 L) and finally 3:2
 20 hexane/ ethyl acetate (as needed) until the benzyl 6- β -hydroxymethyl-6- α -bromo-penicillanate sulfone was removed. Yield 205.5 g (23 %). M.P. 120-121 °C. (CDCl₃) ¹HNMR δ 1.28 (s, 3H), 1.57 (s, 3H), 4.09 (d, 1H, J = 16Hz), 4.54 (s, 1H), 4.62 (d, 1H, J = 16Hz), 4.82
 25 (s, 1H), 5.18 (d, 1H, J = 16 Hz), 5.32 (d, 1H, J = 16 Hz), 7.36-7.42 (m, 5H).

Step 4 - Preparation of 4-Thia-1-azabicyclo
[3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-
 30 dimethyl-7-oxo-,4,4-dioxide, monosodium salt, (2S,5R,6R)

Water (163 mL), ethyl acetate (2000 mL), benzyl 6- β -hydroxymethyl-6- α -bromopenicillanate sulfone (180 g), triethylamine (90.0 g) and 5% palladium on carbon (45 g) were combined and hydrogenated at 50 psi at ambient
 35 temperature for approximately 2 hours. A TLC of the

5 reaction mixture showed the reaction was not complete so additional catalyst (15 g) was added and the mixture was hydrogenated for one hour. Once the reaction was complete, the reaction was quenched with a mixture of sulfuric acid (112.5 g) and water (270 mL). The
 10 reaction mixture was filtered to remove catalyst, and washed with EtOAc (450 mL). The aqueous layer was washed with EtOAc (3 x 750 mL). The organic phases were combined and dried with calcium chloride to a water content of less than 1%. The calcium chloride was then
 15 filtered out and the ethyl acetate was reduced to $\frac{1}{2}$ its volume. Fresh ethyl acetate was then back added to the solution and the water content of the solution was now 0.09%. Sodium ethyl hexanoate (59 g) and EtOAc (450 mL) were combined and added slowly to organic phase at
 20 ambient temperature. The mixture was then allowed to granulate for a period of 30 to 45 minutes. The resulting solids were filtered, washed with EtOAc (500 mL) and dried to give 79.0 g (66%) of sodium 6- β -hydroxymethylpenicillanate sulfone. The solids were
 25 further purified via a recrystallized from 2-propanol/water. M.P. 246-245 °C. ^1H NMR (D_2O) δ 1.23 (s, 3H), 1.39 (s, 3H), 3.82-3.89 (m, 1H), 3.97-4.10 (m, 3H), 4.85 (s, 1H).

30 Alternate Step 4 - Preparation of 4-Thia-1-azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-,4,4-dioxide, monosodium salt, (2S,5R,6R)

Benzyl 6- β -hydroxymethyl-6- α -bromopenicillanate sulfone (1143 g) was placed in a large reaction vessel.
 35 Benzene (6.2 L) and tributyltin hydride (770 mL) were

5 added and the reaction mixture heated to reflux
temperature for 2-3 hours. The reaction was monitored
by TLC, solvent = 1:1 hexane/ Ethyl acetate.

Upon reaction completion the mixture was
concentrated to an oil to remove the benzene. The oil
10 was washed with hexane at ambient temperature, until all
the residual tin byproducts were removed. The material
was reheated to reflux; ethyl acetate (EtOAc) was added
to transfer material to single necked flask and
concentrated. The material was washed with hexane (3 x)
15 and the product layer dried under reduced pressure.

Half of the oil (549 g) was chromatographed over
silica gel (1 Kg), with enough methylene chloride to get
oil into solution, eluting with 7:3 hexane/EtOAc going
to 3:2 hexane/EtOAc. The product fractions were
20 combined and concentrated.


The oil (~540 g) was placed in an autoclave.
Tetrahydrofuran (1.9 L), 10% palladium on carbon and
water (300 mL) were added, and the reaction mixture
hydrogenated at 50 psi, at a temperature of 30 °C, for
25 approximately 1 hour. Upon reaction completion the
reaction mixture was filtered through celite, to remove
catalyst.

The filtrate was concentrated and diluted with
EtOAc (3.0 L). The aqueous layer was washed with EtOAc
30 (1.0 L). The combined organic layers were dried with
calcium chloride, and concentrated to half volume.
EtOAc (2.5 L) was added followed dropwise by a solution
of sodium ethyl hexanoate (SEH, 250 g) and EtOAc (1.05
L). The resulting solids were removed by filtration and
35 dried in a vacuum oven.

5 To the resulting solids, water (6-800 mL) was added and the pH adjusted to between 0.5 and 1.0 with 4M sulfuric acid. The product was extracted with EtOAc (5 x 1.0 L). The combined organic phases were dried with calcium chloride and filtered through a sparkle filter.
 10 The filtrate was reduced to half volume and a solution of SEH (115.3 g) and EtOAc (500 mL) added. The mixture was allowed to granulate. The resulting solids were filtered and washed with EtOAc to give desired product.

15 Example 3

Prodrug 1: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (benzoyloxy)methyl ester, 4,4-dioxide (2S,5R,6R)



20

Prodrug 1, shown above, was prepared as follows.


To a stirred solution of 3.13 g (18.4 mmol.) chloromethyl benzoate (Narchem) in 200 mL acetone was
 25 added 13.8 g (92.1 mmol.) sodium iodide (Aldrich). The resulting mixture was stirred at room temperature overnight. To this solution was added 3.5 g (12.3 mmol.) 4-thia-1-azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide,
 30 monosodium salt, (2S,5R,6R). The reaction mixture was stirred overnight at room temperature. The reaction

5 mixture was then concentrated in vacuo. Subsequently,
 200 mL water and 200 mL ethyl acetate were added and the
 organic layer was separated and washed with brine, dried
 over Na₂SO₄, filtered and concentrated in vacuo.
 Chromatography on silica gel eluting with 1:1 ethyl
 10 acetate/ hexanes afforded 8.62 g of an oil. The oil was
 then recrystallized from ethyl acetate/hexanes yielding
 5.5 g of crystalline solid. The mother liquor still
 contained desired compound. Melting point = 102 °C. ¹H-
 NMR (DMSO): 7.97 (d, 2H, J=7.5Hz), 7.70 (t, 1H,
 15 J=7.5Hz), 7.56 (t, 2H, J=7.5Hz), 6.12 (d, 1H, J=6Hz),
 5.99 (d, 1H, J=6Hz), 5.19 (d, 1H, J=5Hz), 5.17 (m, OH),
 4.62 (s, 1H), 4.20 (m, 1H), 4.03 (m, 1H), 3.73 (m, 1H),
 1.41 (s, 3H), 1.28 (s, 3H).

20

Example 4

Prodrug 2: 4-Thia-1-azabicyclo[3.2.0]heptane-2-
carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -
1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R)



25

Prodrug 2, shown above, was prepared as follows.


To a stirred solution of 2.5 g (8.77 mmol.) 4-thia-
 1-azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-
 (hydroxy-methyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide,
 30 monosodium salt, (2S,5R,6R) in 20 mL DMF was added 2.1 g

5 (11.4 mmol.) (+/-)-benzoic acid 1-chloro-ethyl ester.
 The resulting mixture was then heated to 35 °C for 3
 days. 40 mL water and 100 mL ethyl acetate were added
 and the layers were separated. The aqueous layer was
 extracted with ethyl acetate. The combined organic
 10 layers were washed with water, brine, dried over Na₂SO₄,
 filtered and concentrated in vacuo. Chromatography on
 silica gel eluting with 1 L of 20 % ethyl acetate/ 80 %
 hexanes followed by 1 L 1:1 ethyl acetate/ hexanes
 afforded 1.2 g of an oil that was recrystallized using
 15 ethyl acetate/ hexanes affording 1 g of white
 crystalline solid (mixture of 2 diastereomers). Melting
 point = 133-135°C. ¹H-NMR (d-DMSO, 400MHz): 7.96 (d,
 2H, J=7.5Hz), 7.71 (t, 1H, J=7.5Hz), 7.55 (t, 2H,
 J=7.5Hz), 7.07 (q, 0.5H, J=5.4Hz), 7.03 (q, 0.5H,
 20 J=5.4Hz), 5.19 (d, 1H, J=5Hz), 5.15 (m, OH), 4.54 (s,
 0.5H), 4.53 (s, 0.5H), 4.19 (m, 1H), 4.01 (m, 1H), 3.73
 (m, 1H), 1.62 (d, 1.5H, J=5.4Hz), 1.61 (d, 1.5H,
 J=5.4Hz), 1.44 (s, 1.5H) 1.38 (m, 4.5H).

25

Example 5

Prodrug 3: 4-Thia-1-azabicyclo[3.2.0]heptane-2-
carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-
, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R)



30


5 Prodrug 3, shown above, was prepared by the method
of Example 4 by substituting (S)-Benzoic acid 1-chloro-
ethyl ester and only heating to 30 °C. Melting Point =
154 °C. ¹H NMR (d-DMSO, 400 MHz): 7.96 (d, J= 7.5 Hz,
2H), 7.71 (t, J= 7.5 Hz, 1H), 7.55 (t, J= 7.5 Hz, 2H),
10 7.03 (q, J= 5.4 Hz, 1H), 5.19 (d, J= 5 Hz, 1H), 5.15 (m,
OH), 4.53 (s, 1H), 4.18 (m, 1H), 4.02 (m, 1H), 3.72 (m,
1H), 1.61 (d, J= 5.4Hz, 3H), 1.39 (s, 3H), 1.37 (s, 3H).
[α]_D = +119 (c = 0.0121, CHCl₃)

Prodrug 3 was also prepared by the following
15 alternative route. 52.03 g (182.4 mmol.) of 4-thia-1-
azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-,4,4-dioxide,
monosodium salt, (2S,5R,6R), 61.50 g (181.1 mmol.) of
tetrabutylammonium hydrogen sulfate, and 15.44 g (183.2
20 mmol.) of sodium hydrogen carbonate were combined at 20
°C. To this was added 400 mL dichloromethane while
maintaining a temperature of 20 °C. Next 100 mL of water
was added. The resulting mixture was stirred at 20 °C
for 30 minutes. Organic layer was separated and dried
25 over sodium sulfate, filter and concentrated in vacuo.
To the resulting residue was added 169.4 g (917.6 mmol.)
(S)-Benzoic acid 1-chloro-ethyl ester followed by 160 mL
acetone. The resulting solution was then stirred for 3
days at room temperature. Reaction was concentrated in
30 vacuo and chromatographed on silica gel using 40-50 %
ethyl acetate/ hexanes as eluent. The resulting product
was crystallized from ethanol followed by
recrystallization from ethyl acetate/ hexanes.

5 Filtration and drying in vacuo yielded 85.9 g of white crystalline product.

Example 6

10 Prodrug 4: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1S)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R)




Prodrug 4, shown above, was prepared by the method
 15 of Example 4 by substituting (R)-benzoic acid 1-chloro-ethyl ester and only heating to 30 °C. ¹H-NMR (d-DMSO, 400MHz): 7.96 (d, 2H, J=7.5Hz), 7.71 (t, 1H, J=7.5Hz), 7.55 (t, 2H, J=7.5Hz), 7.07 (q, 1H, J=5.4Hz), 5.19 (d, 1H, J=5Hz), 5.15 (m, OH), 4.54 (s, 1H), 4.18 (m, 1H),
 20 4.01 (m, 1H), 3.72 (m, 1H), 1.62 (d, 3H, J=5.4Hz), 1.44 (s, 3H) 1.35 (s, 3H). MS (m/z): 410 (M⁻ -1, 100).

5


Example 7

Preparation of Carbonic Acids For Synthesizing
Comparison Prodrugs of 4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylic acid,6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide
(2S,5R,6R)


10




Carbonic acid chloromethyl ester isopropyl ester, shown above, was prepared as follows. To a stirred solution of 10 grams (75.2 mmol.) chloromethyl chloroformate (Fluka) in 100 mL dichloromethane at 0 °C was added 5.8 mL (76 mmol.) isopropyl alcohol followed by 11.93 g (97.8 mmol.) dimethyl amino pyridine (Fluka). The resulting reaction mixture was then allowed to warm to room temperature and stir overnight. The reaction mixture is then diluted with water. The layers were then separated. The organic layer was washed with brine, dried over MgSO₄ filtered and concentrated in vacuo yielding 6 grams of a clear oil. The oil was then carried forwarded as is. ¹H-NMR (CDCl₃, 400 MHz): 5.72 (s, 2H), 4.95 (m, 1H, J= 6.2Hz), 1.33 (d, 6H, J=6.2Hz). Note: Better yields are achieved when only 1.05 equivalents of dimethyl amino pyridine are used.




5 (+/-)-Carbonic acid 1-chloro-ethyl ester isopropyl
 ester was prepared analogous to carbonic acid
 chloromethyl ester isopropyl ester by substituting
 chloroethyl chloroformate (Fluka). $^1\text{H-NMR}$ (CDCl_3 , 400
 MHz): 6.41 (q, 1H, $J=5.8$), 4.94 (m, 1H, $J=6.2\text{Hz}$), 1.81
 10 (d, 3H, $J=5.8$), 1.32 (m, 6H).



(+/-)-Carbonic acid 1-chloro-ethyl ester propyl
 15 ester was prepared analogous to carbonic acid
 chloromethyl ester isopropyl ester by substituting
 propanol (Aldrich). $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): 6.41 (q,
 1H, $J=5.8$), 4.17 (m, 2H), 1.81 (d, 3H, $J=5.8$), 1.71 (m,
 2H), 0.96 (m, 3H).




(+/-)-Carbonic acid butyl ester 1-chloro-ethyl
 ester was prepared analogous to carbonic acid
 25 chloromethyl ester isopropyl ester by substituting n-
 butanol (Aldrich). $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): 6.41 (q, 1H,
 $J=5.8$), 4.20 (m, 2H), 1.81 (d, 3H, $J=5.8$), 1.67 (m, 2H),
 1.41 (m, 2H), 0.93 (m, 3H).




5 Carbonic acid chloromethyl ester propyl ester was prepared analogous to carbonic acid chloromethyl ester isopropyl ester by substituting propanol (Aldrich). ^1H -NMR (CDCl_3 , 400 MHz): 5.72 (s, 2H), 4.18 (t, 2H, $J=6.6\text{Hz}$), 1.71 (m, 2H), 0.97 (t, 3H, $J=7.5\text{Hz}$).

10




Carbonic acid butyl ester chloromethyl ester was prepared analogous to carbonic acid chloromethyl ester isopropyl ester by substituting n-butanol (Aldrich). ^1H -NMR (CDCl_3 , 400 MHz): 5.72 (s, 2H), 4.23 (t, 2H, $J=6.6\text{Hz}$), 1.70 (m, 2H), 1.41 (m, 2H), 0.94 (t, 3H, $J=7.5\text{Hz}$).




20

(+/-)-5-Bromo-5H-furan-2-one was prepared analogous to Tett. Lett. 22, 34, 1981, 3269-3272.



25

5 Acetic acid-1-chloro-1-methyl ethyl ester was
 Prepared as in Neuenschwander et al., *Helvetica Chimica*
 1978; 61: 2047-2058.




10

Carbonic acid chloromethyl ester ethyl ester was
 prepared analogous to carbonic acid chloromethyl ester
 isopropyl ester by substituting ethanol. ¹H-NMR (CDCl₃,
 400 MHz): 5.72 (s, 2H), 4.28 (q, 2H, J= 7.1Hz), 1.34 (t,
 15 3H, J=7.1Hz).

Example 8

Preparation of Comparison Prodrugs of
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
 20 (hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide
(2S,5R,6R)

Prodrugs of 4-thia-1-azabicyclo[3.2.0]heptane-2-
 carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-,
 25 4,4-dioxide (2S,5R,6R) were prepared to demonstrate the
 unexpectedly improved bioavailability, and physical
 properties, of the prodrugs of the present invention.
 Of these Comparison Prodrugs, Comparison Prodrug 1 is
 described in Example 25 of U.S. Patent No. 4,287,181.
 30 Comparison Prodrugs 2-15 are novel compounds but fall
 within the scope of the genus disclosed in U.S. Patent
 No. 4,287,181.

5 Comparison Prodrug 1:


10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy) methyl ester, 4,4-dioxide (2S,5R,6R)

To a stirred solution of 2.5 g (8.77 mmol.) 4-thia-1-azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-,4,4-dioxide, monosodium salt, (2S,5R,6R) in 20 mL DMF was added (11.4 mmol.) chloromethyl pivalate (Aldrich) and stirred at room temperature overnight. The resulting mixture was then heated to 35 °C for 3 days. 40 mL water and 100 mL ethyl acetate were added and the layers were separated. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over Na₂SO₄, filtered and concentrated in vacuo. Chromatography on silica gel eluting with 1 L of 20 % ethyl acetate/ 80 % hexanes followed by 1 L 1:1 ethyl acetate/ hexanes yielded an oil. Hexanes (15 mL) were added to the oil and the sample was placed in the refrigerator for 4 days at which point a solid precipitated. It was then concentrated in vacuo yielding 110 mg of white amorphous solid. Melting point

5 = 70-73 °C. ¹H-NMR (CDCl₃, 400 MHz): 5.94 (d, 1H, J=5.4Hz), 5.70 (d, 1H, J=5.4Hz), 4.69 (d, 1H, J=4.1Hz), 4.48 (s, 1H), 4.30 (m, 1H), 4.15 (m, 2H), 1.55 (s, 3H), 1.41 (s, 3H), 1.21 (s, 9H).

Alternately, this compound, which is also known as
 10 pivaloyloxymethyl 6-β-hydroxymethylpenicillinate sulfone, can be prepared as described in Example 25 of U.S. Patent No. 4,287,181.

Comparison Prodrug 2:




15

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-
, [(ethoxycarbonyl)oxy] methyl ester, 4,4-dioxide
 20 (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 1 with the exception that carbonic acid chloromethyl ester ethyl ester was substituted for chloromethyl pivalate. Melting point
 25 (amorphous solid) = 103-105 °C. ¹H-NMR (MeOD, 400 MHz): 5.91 (d, 1H, J=5.8Hz), 5.76 (d, 1H, J=5.8Hz), 4.96 (d,

5 1H, J=4.6Hz), 4.55 (s, 1H), 4.15-4.25 (m, 4H), 3.95 (m, 1H), 1.53 (s, 3H), 1.41 (s, 3H), 1.29 (t, 3H, J=7.1).

Comparison Prodrug 3:




10

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, .6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester, 4,4-dioxide (2S,5R,6R)

15 This prodrug was prepared according to the method used to prepare Comparison Prodrug 1 with the exception that 3-bromo phthalide (Aldrich) was substituted for chloromethyl pivalate.

 Upon dilution of DMF with water the desired product
 20 precipitated as an amorphous solid and was filtered and dried in vacuo. MS (m/z):394 (M⁻) NMR represents a mixture of diastereomers. ¹H-NMR (d-DMSO, 400 MHz):
 7.8-8.0 (m, 4H), 7.60 (s, 0.5H), 7.59 (s, 0.5H), 5.23 (m, 1H), 5.16 (OH), 4.71 (s, 0.5H), 4.67 (s, 0.5H), 4.20
 25 (m, 1H), 4.02 (m, 1H), 3.74 (m, 1H), 1.47 (s, 1.5H), 1.37 (s, 1.5H), 1.36 (s, 1.5H), 1.31 (s, 1.5H).


5 Comparison Prodrug 4:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, [[(1-methylethoxy)carbonyl]oxy] methyl ester, 4,4-dioxide (2S,5R,6R)

To a stirred solution of (18.4 mmol.) carbonic acid chloromethyl ester isopropyl ester in 200 mL acetone was added 13.8 g (92.1 mmol.) sodium iodide (Aldrich). The
 15 resulting mixture was stirred at room temperature overnight. To this solution was added 3.5 g (12.3 mmol.) 4-thia-1-azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide, monosodium salt, (2S,5R,6R) (US 4,287,181) and the
 20 reaction mixture was stirred overnight at room temperature. The reaction mixture was then concentrated in vacuo. 200 mL water and 200 mL ethyl acetate were added and the organic layer was separated and washed with brine, dried over Na₂SO₄, filtered and concentrated
 25 in vacuo. Chromatography on silica gel eluting with 1:1 ethyl acetate/ hexanes. The final product was a reddish oil. MS (m/z):378 (M⁺). ¹H-NMR (d-DMSO, 400 MHz): 5.86 (d, 1H, J=5.8Hz), 5.74 (d, 1H, J=5.8Hz), 5.20 (d, 1H, J=5Hz), 5.17 (m, OH), 4.82 (m, 1H), 4.60 (s, 1H),

5 4.20 (m, 1H), 4.03 (m, 1H), 3.74 (m, 1H), 1.42 (s, 3H),
1.30 (s, 3H), 1.22 (d, 6H, J=6.2Hz).


Comparison Prodrug 5:



10


4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, .6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 1-[[[(1-methylethoxy)carbonyl]oxy] ethyl ester, 4,4-dioxide (2S,5R,6R)

15 This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that carbonic acid 1-chloro-ethyl ester isopropyl ester was substituted for carbonic acid chloromethyl ester isopropyl ester. MS (m/z):392 (M⁻). NMR is of a reddish
20 oil that is a mixture of 2 diastereomers ¹H-NMR (d-DMSO, 400 MHz): 6.71 (q, 0.5H, J=5.4Hz), 6.67 (q, 0.5H, J=5.4Hz), 5.20 (d, 1H, J=5Hz), 4.79 (m, 1H), 4.51 (s, 0.5H), 4.49 (s, 0.5H), 4.20 (m, 1H), 4.03 (m, 1H), 3.74 (m, 1H), 1.48 (m, 3H), 1.43 (s, 1.5H), 1.39 (s, 1.5H),
25 1.33 (m, 3H), 1.22 (m, 6H).

5 Comparison Prodrug 6:


10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, .6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, 1-
[(propoxycarbonyl)oxy]ethyl ester, 4,4-dioxide
(2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that carbonic acid 1-chloro-ethyl ester propyl ester was substituted for carbonic acid chloromethyl ester isopropyl ester. MS (m/z):392 (M⁻). NMR is of a yellow-reddish oil that is a mixture of 2 diastereomers ¹H-NMR (d-DMSO, 400 MHz): 6.72 (q, 0.5H, J=5.4Hz), 6.68 (q, 0.5H, J=5.4Hz), 5.20 (m, 1H), 4.51 (s, 0.5H), 4.49 (s, 0.5H), 4.20 (m, 1H), 4.03 (m, 3H), 3.74 (m, 1H), 1.59 (m, 2H), 1.48 (m, 3H), 1.39 (s, 1.5H), 1.34 (s, 1.5H), 1.22 (m, 3H), 0.86 (m, 3H).

5 Comparison Prodrug 7:


10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, 1-
[(butoxycarbonyl)oxy]ethyl ester, 4,4-dioxide (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that carbonic acid butyl ester 1-chloro-ethyl ester was substituted for carbonic acid chloromethyl ester isopropyl ester. MS (m/z):406 (M⁻). NMR is of a yellow-reddish oil that is a mixture of 2 diastereomers ¹H-NMR (d-DMSO, 400 MHz): 6.72 (q, 0.5H, J=5.4Hz), 6.68 (q, 0.5H, J=5.4Hz), 5.20 (m, 1H), 4.51 (s, 0.5H), 4.49 (s, 0.5H), 4.20 (m, 1H), 4.03 (m, 3H), 3.74 (m, 1H), 1.59 (m, 2H), 1.15-1.55 (m, 11H), 0.86 (m, 3H).

5 Comparison Prodrug 8:


10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-
, [(propoxycarbonyl)oxy]methyl ester, 4,4-dioxide
(2S,5R,6R)

This prodrug was prepared according to the method used to prep
 isopropyl ester. The final product was an amorphous
 white solid. MS (m/z): 378 (M⁻). ¹H-NMR (d-DMSO, 400
 15 MHz): 5.86 (d, 1H, J=6.2Hz), 5.74 (d, 1H, J=6.2Hz),
 5.20 (d, 1H, J=5Hz), 5.17 (m, OH), 4.60 (s, 1H), 4.20
 (m, 1H), 4.10 (m, 2H), 4.03 (m, 1H), 3.74 (m, 1H), 1.60
 (m, 2H), 1.42 (s, 3H), 1.30 (s, 3H), 0.86 (t, 3H,
 J=7.5Hz).

5 Comparison Prodrug 9:


10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, .6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-
, [(butoxycarbonyl)oxy]methyl ester, 4,4-dioxide
(2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception
 15 that carbonic acid butyl ester chloromethyl ester was substituted for carbonic acid chloromethyl ester isopropyl ester. The final product was an amorphous white solid. MS (m/z):392 (M⁻). ¹H-NMR (d-DMSO, 400 MHz): 5.86 (d, 1H, J=6.2Hz), 5.74 (d, 1H, J=6.2Hz),
 20 5.20 (d, 1H, J=5Hz), 5.17 (m, OH), 4.60 (s, 1H), 4.20 (m, 1H), 4.15 (m, 2H), 4.03 (m, 1H), 3.74 (m, 1H), 1.60 (m, 2H), 1.42 (s, 3H), 1.30 (m, 2H), 1.30 (s, 3H), 0.86 (t, 3H, J=7.5Hz) ..

5 Comparison Prodrug 10:


10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, .6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-,2,5-dihydro-5-oxo-2-
furanyl ester, 4,4-dioxide (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that 5-bromo-5H-furan-2-one was substituted for
 15 chloromethyl pivalate. MS (m/z):344 (M⁻). NMR is a mixture of 2 diastereomers. The product was an amorphous solid. ¹H-NMR (d-DMSO, 400 MHz): 7.81 (m, 0.5H), 7.73 (m, 0.5H), 7.14 (m, 0.5H), 7.10 (m, 0.5H), 6.61 (m, 1H), 5.21 (m, 1H), 5.17 (m, OH), 4.67 (s,
 20 0.5H), 4.63 (s, 0.5H), 4.20 (m, 1H), 4.03 (m, 1H), 3.74 (m, 1H), 1.42 (s, 1.5H), 1.40 (s, 3H), 1.32 (s, 1.5H).

5 Comparison Prodrug 11:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1-oxobutoxy) methyl
ester, 4,4-dioxide (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that chloromethyl butyrate (Acros organics) was substituted for chloromethyl pivalate. The product was a clear oil. MS (m/z): 362 (M⁺). ¹H-NMR (d-DMSO, 400 MHz): 5.86 (d, 1H, J=5.8Hz), 5.74 (d, 1H, J=5.8Hz), 5.20 (d, 1H, J=5.8Hz), 5.17 (m, OH), 4.55 (s, 1H), 4.20 (m, 1H), 4.01 (m, 1H), 3.74 (m, 1H), 2.35 (m, 2H), 1.52 (m, 2H), 1.40 (s, 3H), 1.30 (s, 3H), 0.86 (m, 3H).


5 Comparison Prodrug 12:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, .6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-,1,3-dihydro-3-oxo-1-
isobenzofuranyl ester, 4,4-dioxide (2S,5R,6R)

Prepared by chromatography on silica gel of 275 mg of Comparison Prodrug 3 using 5% isopropyl alcohol/ 95% methylene chloride yielded 200mg of a mixture of

15 diastereomers followed by 70 mg of a single, (more polar) diastereomer. The product was an amorphous solid. MS (m/z):394 (M⁻) NMR represents the more polar diastereomer. ¹H-NMR (d-DMSO, 400 MHz): 7.95 (d, 1H, J=7.5Hz), 7.90 (m, 1H), 7.81 (d, 1H, J=7.5Hz), 7.77 (m,


20 1H), 7.60 (s, 1H), 5.23 (d, 1H, J=5Hz), 5.16 (OH), 4.71 (s, 1H), 4.20 (m, 1H), 4.02 (m, 1H), 3.74 (m, 1H), 1.47 (s, 3H), 1.37 (s, 3H).

5 Comparison Prodrug 13:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,.6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, (acetyloxy) methyl
ester, 4,4-dioxide (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 1 with the exception that bromomethyl acetate (Aldrich) was substituted for
 15 chloromethyl pivalate. The final product was a viscous oil. MS (m/z):334 (M⁻). ¹H-NMR (d-DMSO, 400 MHz):
 5.82 (d, 1H, J=6.2Hz), 5.72 (d, 1H, J=6.2Hz), 5.19 (d, 1H, J=5Hz), 5.17 (m, OH), 4.55 (s, 1H), 4.20 (m, 1H),
 4.01 (m, 1H), 3.74 (m, 1H), 2.08 (s, 3H), 1.40 (s, 3H),
 20 1.30 (s, 3H).

5 Comparison Prodrug 14:



10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, .6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 1-(acetyloxy) -1-methylethyl ester, 4,4-dioxide (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 1 with the exception that acetic acid-1-chloro-1-methyl ethyl ester was substituted for chloromethyl pivalate. The final product was an amorphous solid. MS (m/z):362 (M⁻). ¹H-NMR (CDCl₃, 400 MHz): 4.68 (d, 1H, J=5.0Hz), 4.40 (s, 1H), 4.31 (m, 1H), 4.15 (m, 2H), 2.06 (s, 3H), 1.92 (s, 3H), 1.82 (s, 3H), 1.58 (s, 3H), 1.47 (s, 3H).

20

Example 9

Chemical (pH), Suspension and Plasma Stability

The stability of Prodrug 3 was evaluated with regards to (1) chemical stability while in solutions of various pH, (2) maintaining potency while in suspension, and (3) chemical stability in plasmas from various mammals to assess the ability of Prodrug 3 to resist hydrolysis prior to absorption and then to rapidly hydrolyze to form 6-β-HMPAS after absorption.

5 Chemical stability of Prodrug 3, in solution, as
compared to the sodium salt of 6- β -HMPAS (hereinafter
"Na HPMAS") and lithium clavulanate in solution, was
assessed at pH 1, 2, 2.5, 4.0, 5.0, 6.5, and 7.4.
Buffers were appropriately formulated to achieve the
10 desired pH of each incubation. The incubation consisted
of 990 μ l of the appropriate pH buffer and was initiated
with the addition of 10 μ l of a 10 mM stock of compound
in 100% methanol (final concentration = 100 μ M). Serial
samples (20 μ l) were taken at 0, 10, 20, 40, 60, 120,
15 and 240 minutes by an auto injector and injected
directly onto an HPLC in-line with a LC/MS single
quadropole mass spectrometer system used for analyte
detection. The temperature of the incubation was
regulated with a 96-well heat block. Incubations were
20 performed at 25°C and 37°C. The LC/MS system was run in
the negative ion mode. Selective ion monitoring of the
appropriate $[M-H]^-$ for each analyte was used for
detection and quantitation of remaining compound at each
timepoint. The peak response at each time point was
25 expressed as a percentage of that obtained at time = 0.
A degradation rate constant (k_d) was obtained by
regression of these percentages from time = 0 minutes to
time = 240 minutes. An apparent first-order half-life
could then be estimated as $\ln 2/k_d$. These determinations
30 were completed in duplicate and the average was
reported.

As shown in the following table, Prodrug 3
demonstrated excellent acid stability and adequate
stability near neutral pH for absorption. Also, Na-

5 HMPAS demonstrated superior solution stability compared to clavulanate, particularly at low pH.

The stability of Prodrug 3 in suspension (unbuffered in 0.5% methylcellulose at 25 °C) was also evaluated to determine the effect of time in suspension
10 upon potency. As shown below, Prodrug 3 maintained greater than 90% of its potency after storage at room temperature for 10 days. By contrast, only 40% of potency is retained with clavulanate in the Augmentin suspension if left at room temperature for the same time
15 period (See Mehta, A.C., S. Hart-Davies, J. Payne and R.W. Lacey, 1994. Stability of amoxicillin and potassium clavulanate in a co-amoxicillin-clavulanate oral suspension. *J. Clin. Pharm. Ther.* 19:313-315.).

5

	pH					
Solution Stability (100 µM)	7.4	6.5	5.0	4.0	2.5	1.2
	Half-life (Hours)					
Prodrug 3 (25 °C)	2.7	>24	>24	>24	>24	>24
Prodrug 3 (37 °C)	0.6	4.5	>24	>24	>24	>24
Na-HMPAS (25 °C)	>24	>24	>24	>24	>24	>24
Na-HMPAS (37 °C)	>24	>24	>24	>24	>24	>24
Clavulanate (25 °C)	>24	>24	>24	>24	1.2	0.6
Clavulanate (37 °C)	>24	>24	>24	>24	0.9	ND
Prodrug 3 Suspension Stability	Day 1	Day 3	Day 5	Day 7	Day 10	
	Potency (percent)*					
1.51 mg/ml** (10 mg/kg rat dose preparation)	ND	103	98	104	91**	*

*Potency assessed as a percentage of the target concentration as assayed by LC/MS of solubilized standards. Values represent an average of duplicate determinations. ND = not determined

** pH of initial suspensions ~6.8 and fell to 4.7 by day 10

*** diastereomer mixture essentially unchanged ~ 95:5

15 Plasma stability of Prodrug 3, Na-HMPAS and lithium clavulanate were determined, in mouse, rat, dog, monkey

5 and human plasma, using plasma that was prepared and
subjected to one freeze/thaw cycle prior to use. The
incubation consisted of 990 μ l of plasma preincubated
for 5 minutes at 37 °C in a 96-well heat block. The
incubation was initiated with the addition of 10 μ l of a
10 10 mM stock of compound in 100% methanol. Serial
aliquots (100 μ l) were removed and transferred to 200 μ l
of 75/25 acetonitrile/3% perchloric acid at 0, 1, 2, 5,
10, 20, 30, and 60 minutes. The samples were
centrifuged, the supernatants transferred to injection
15 vials, and 20 μ l was injected onto the HPLC in-line with
a LC/MS single quadropole mass spectrometer. The LC/MS
system was run in the negative ion mode. Selective ion
monitoring of the appropriate $[M-H]^-$ for each analyte was
used for detection and quantitation of remaining
20 compound at each timepoint. The peak response at each
time point was expressed as a percentage of that
obtained at time = 0. A degradation rate constant (k_d)
was obtained by regression of these percentages from
time = 0 minutes to time = 240 minutes. An apparent
25 first-order half-life was then be estimated as $\ln 2/k_d$.
These determinations were completed in duplicate and the
average was reported as shown below.

5

Plasma Stability (100 μ M)	Mouse	Rat	Dog	Monkey	Human
	Half-life				
Prodrug 3 37 °C	2.8 min	<2.0 min	2.8 min	3.6 min	<2.0 min
Na-HMPAS 37 °C	3.9 hr	3.4 hr	> 4 hr	>4 hr	>4 hr
Clavulanate 37 °C	>4 hr	3.3 hr	2.8 hr	3.6 hr	2.6 hr

Prodrug 3 demonstrated excellent acid stability and adequate stability near neutral pH for absorption. Hydrolysis rates of Prodrug 3 in the plasma of all species tested, demonstrate efficient enzymatic hydrolysis to yield 6- β -HMPAS upon absorption. Na-HMPAS demonstrated superior solution stability compared to clavulanate, particularly at low pH. Although both compounds are labile in plasma, Na-HMPAS shows improved human plasma stability.

Example 10

Inhibitory activity of Prodrug 3 at intestinal pH values

It is thought that clavulanate produces diarrhea in the human GI tract since it combines with residual amoxicillin to selectively kill essential components of the normal flora. Clavulanate is not a prodrug, and

5 thus the 40% that remains unabsorbed from the intestine
is the same active molecule as the 60% that is absorbed
into circulation. While the pH of the stomach and
proximal small intestine is acidic, in a study by Berry,
V. et al., *Efficacy of a pharmacokinetically enhanced*
10 *formulation of amoxicillin/clavulanate against*
experimental respiratory tract infection in rats caused
by Streptococcus pneumoniae, Abstract B988, 41st
Inter-science Conference on Antimicrobial Agents and
Chemotherapy, December 16-19th, 2001 Chicago, IL., found
15 that the median pH of 24h stool samples collected from
subjects with diarrhea was 6.4 (range 5.4-7.8).

As shown in Example 7, Prodrug 3 is very stable and
does not readily convert to 6- β -HMPAS at pH < 6.5. In
order to compare the beta-lactamase inhibitory activity
20 of Prodrug 3 and Na-HMPAS under pH conditions found in
the human large intestine, we determined the IC₅₀ of both
compounds against a TEM-1 beta-lactamase at pH 6.0 and
7.0. The data indicate that at pH 6.0, where there
should be no conversion of the prodrug to the active
25 form of the inhibitor, Prodrug 3 is inactive against
TEM-1 beta-lactamase (IC₅₀ >100 μ M). In contrast, at pH
7.0 where conversion of the prodrug to active inhibitor
occurs with a half-life of 33 minutes, the resulting 6-
 β -HMPAS generated results in a much greater level of
30 inhibition of this beta-lactamase than was observed at
pH 6.0.

5

		IC ₅₀ (μM)	
		<u>Prodrug 3</u>	<u>6-β-HMPAS</u>
	E. coli TEM-1 pH 6.0	> 100	0.37
10	E. coli TEM-1 pH 7.0	2.2	0.12

Example 11

Absorption (Oral In Vivo Bioavailability)

As Prodrug 3 has a solution half-life of 30 minutes
 15 at neutral pH and, in the presence of esterases, the
 prodrug is hydrolyzed within a few minutes, an *in vitro*
 assessment using the human Caco-2 cell line was
 determined to be inappropriate to measure prodrug
 absorption. Instead, an *in vivo* model for absorption
 20 was found to be more relevant for assessing absorption
 of the prodrugs of the present invention. Further, the
 correlation of fraction absorbed in the rat to that of
 human has been studied in several marketed agents and
 the correlation has been shown to be quite good (corr =
 25 0.971) (See Chiou, W.L. and A. Barve, 1998. Linear
 correlation of the fraction of oral dose absorbed of 64
 drugs between humans and rats. *Pharm. Res.* 15:1792-
 1795.). Based upon this correlation, the rat was used
 to predict human absorption. It should be further
 30 appreciated that 6-β-HMPAS demonstrated minimal hepatic
 extraction as suggested by rat and human hepatocytes.
 Thus, oral bioavailability assessments in rats should
 correlate well with the fraction absorbed in humans.

Estimates of oral bioavailability were conducted on

5 Na-HMPAS, Prodrugs 1, 2, 3 and 4, as well as the
fourteen comparison prodrugs of Example 8, each using
sets of three Sprague-Dawley rats (200-225 gm) equipped
with surgically implanted jugular vein catheters. The
selection of dose vehicles, for the oral studies,
10 depended upon the physical state of the compound being
tested. All compounds that were orally administered,
with the exception of Prodrug 1, were in the form of an
oil or an amorphous solid. As such, these compounds
were administered in a solution (PO) dosage form using a
15 70/20/10 water/Chremophore/ethanol vehicle.

The oral prodrug doses were prepared to deliver a
10 mg/kg equivalent dose of 6- β -HMPAS at a dose volume
of 10 ml/kg. Na-HMPAS was administered intravenously
at a dose of 10 mg/kg to establish bioavailability
20 estimates (6- β -HMPAS equivalent).

Blood samples were taken at 0, 15, 30 min., 1, 2,
3, and 5 hr. after dosing. The samples were then
processed for plasma and stored at -20 °C prior to
analysis. Samples were assayed for 6- β -HMPAS, as
25 described below, and then the mean concentration versus
time profiles for oral and intravenous administration
were determined. The area under the plasma
concentration versus time curve ($AUC_{0-t_{last}}$) was
calculated from time 0 to the last quantifiable
30 timepoint using linear trapezoidal approximation. The
terminal elimination rate constant (K_{el}) was estimated by
regression of the plasma concentration data from the
apparent beginning of the elimination phase to the last
sample point. An elimination half-life was estimated as
35 $\ln 2/K_{el}$. The area from t_{last} to infinity ($AUC_{t_{last}-\infty}$)

5 was estimated at $C_{est_{t_{last}}}/K_{el}$ where $C_{est_{t_{last}}}$ represents the estimated concentration at the last time point in which drug was quantified based on the regression analysis. The total area under the curve ($AUC_{0-\infty}$) was estimated as the sum of $AUC_{0-t_{last}}$ and $AUC_{t_{last}-\infty}$. Bioavailability (F)

10 was expressed as $AUC_{(0-\infty)po} \times Dose_{iv} / AUC_{(0-\infty)iv} \times Dose_{po}$.

The mean bioavailabilities found were as shown below.

5

Compound	Mean Bioavailability	Standard Deviation
Na-HMPAS	6.0	1.6
Prodrug 1	113.1	10.7
Prodrug 2	102.0	11.1
Prodrug 3	92.4	6.0
Prodrug 4	111.1	8.8
Comparison Prodrug 1	55.4	4.7
Comparison Prodrug 2	6.2	1.0
Comparison Prodrug 3	27.2	2.6
Comparison Prodrug 4	6.8	0.9
Comparison Prodrug 5	46.5	1.4
Comparison Prodrug 6	60.9	6.1
Comparison Prodrug 7	40.3	10.8
Comparison Prodrug 8	7.9	1.5
Comparison Prodrug 9	12.3	2.0
Comparison Prodrug 10	10.9	1.7
Comparison Prodrug 11	33.1	5.4
Comparison Prodrug 12	20.4	1.0
Comparison Prodrug 13	37.6	3.7
Comparison Prodrug 14	15.4	3.9

As shown above, the prodrugs of the present invention have significantly better bioavailabilities than does 6- β -HMPAS, the previously known Comparison

5 Prodrug 1, or the prior generically disclosed prodrugs
(Comparison Prodrugs 2-14).

Assay Description:

10 In this assay, the analytes of interest were back
extracted into the aqueous phase following acetonitrile
precipitation and treatment with chloroform. This
provided approximately a 2 fold concentration factor
without having an evaporation and reconstitution step.

15 Detection was afforded through the use of LC/MS/MS
in negative ion operation. Single quadrapole operation
was inadequate for selective detection of the analyte.

The pH of the loading solvent (95:5 20 mM ammonium
formate/acetonitrile; solvent A) was ~ 5.0.

20 The analytical column was an Phenomenex AQUA C18
4.6 x 50 mm.

All sample preparation was completed in 96-well 1.2
mL MARSH-tubes. The samples were prepared as follows.
The Plasma sample (200 µl) was added to 400 µl of 95:5
acetonitrile:20 mM ammonium formate containing 5 µg/ml
25 sulbactam as an internal standard. The samples were
centrifuged at 3000 rpm for 10 min in a table top
centrifuge. The supernatant (400 µl) was then
transferred to clean 1.2 ml MARSH[®] tubes. Chloroform
(600 µl) was added to the samples, which were then
30 mixed, and subsequently centrifuged at 3000 rpm for 10
minutes. The transferred aqueous phase was then removed
from top (~ 100 µl) and then analyzed.

5 Mass Spectrometry Conditions:

Mass Spectrometer: API-3000 operated in negative ion mode using Turbo spray (electrospray)

Ionization voltage: -3000V

Orifice voltage: -25 eV

10 Collision energy: 30 eV

Nebulization and Heat gas adjusted as needed

Reaction Monitoring:

6- β -HMPAS: 262 => 218

15 Sulbactam (IS): 232 => 140

Amoxicillin: 364 => 223

Clavulanic acid: 198 => 136

Run time: 3 min.

RT: ~ 2 min for all analytes

20 Injection Volume: 20 μ l

HPLC Conditions:

Solvent A: 95:5 20 mM ammonium formate: acetonitrile

Solvent B: 95:5 acetonitrile: 20 mM ammonium formate

Analytical Flow: 1 ml/min

25 Flow to Mass Spectrometer: ~100 μ l/min

Ballistic Gradient Schedule:

0 - 0.5 min 100 % A

0.5- 1 min 100% A to 100% B

1-1.5 min 100% B

30 1.5 - 2.0 min 100% B to 100% A

LLOQ = 0.1 μ g/ml for 6- β -HMPAS and amoxicillin, 0.5

μ g/ml clavulanic acid

ULOQ = 50 μ g/ml (All)

Regression = linear 1/x weighting

35 Column life ~ 300 - 400 injections

5

Portal Vein Studies in Rats: Systemic exposure of Prodrug 3 was also assessed in portal vein cannulated rats following oral administration of the prodrug at a dose of 100 mg/kg. Whole blood aliquots were stabilized
 10 in ice cold acid immediately upon sampling at 5, 15 and 30 minutes post dose. No levels of Prodrug 3 were detected in any of the samples (assay LLOQ of 100 ng/ml). These results suggest that upon absorption, Prodrug 3 undergoes rapid hydrolysis to yield 6- β -HMPAS
 15 prior to exposure to the liver and circulation throughout the body.

Example 12

In Vitro Screens

20 Biochemical activity against β -lactamases from community respiratory pathogens: Only three beta-lactamase inhibitor molecules exist in the marketplace: sulbactam, clavulanate and tazobactam. All three inhibit type A penicillinases found in a broad range of
 25 bacteria. Of these, only clavulanate is directed toward oral therapy of community respiratory infections. Na-HMPAS was tested against a collection of cell-free penicillinases commonly found in *H. influenzae* and *M. catarrhalis* that are resistant to ampicillin. The data
 30 in the following table indicates that Na-HMPAS is equivalent to lithium clavulanate against the ROB-1 and TEM-1 enzymes from *H. influenzae*. All three beta-lactamase inhibitors were very potent against the BRO-1 and BRO-2 penicillinases found in *M. catarrhalis*, with
 35 sulbactam being the most active (Table 1). A broader

- 5 analysis of β -lactamases from 30 recent clinical isolates of *M. catarrhalis* showed that Na-HMPAS was effective at inhibiting the BRO-1 and BRO-2 enzymes from all of these strains, with an average IC_{50} of 0.19 μM .

IC ₅₀ s of β -lactamase inhibitors against β -lactamases in cell extracts				
	β -lactamase	IC ₅₀ (μM) *		
Strains	Type	Sulbactam	6- β -HMPAS	Clavulanate
<i>H. influenzae</i> ATCC43334	ROB-1	3.40	0.01	0.04
<i>H. influenzae</i> 54A1173	TEM-1	4.78	0.03	0.02
<i>M. catarrhalis</i> 87A1178 ATCC43617	BRO-2	0.03	0.32	0.11
<i>M. catarrhalis</i> 87A1115	BRO-1	0.011	0.143	0.14

- 10 *All inhibitory values are determined against the chromogenic cephalosporin in a colorimetric assay.

Biochemical activity against β -lactamases from other pathogens, including those associated with skin

- 15 infections: Na-HMPAS was comparable to clavulanate in terms of its inhibitory potency against a wide variety of TEM extended spectrum beta-lactamases (ESBLs) while Na-HMPAS and clavulanate were usually comparable in potency against ESBLs.

5

Inhibition of selected extended spectrum β -lactamases (ESBLs) (IC_{50} , μM)				
Inhibitor				
Strains	β -lactamase Type	IC_{50} (μM) *		
		Sulbactam	6- β -HMPAS	Clavulanate
<i>E. coli</i> ATCC35218	TEM-1	6.85	0.14	0.05
<i>E. coli</i> 51A1101	TEM-1	4.76	0.07	0.02
<i>K. pneumoniae</i> CF104	TEM-3	0.55	<0.003	<0.003
<i>K. pneumoniae</i> CF504	TEM-5	4.68	0.08	<0.003
<i>K. pneumoniae</i> B L-1	TEM-10	23.19	0.39	>100
<i>K. pneumoniae</i> MCV37	TEM-12	5.86	0.27	<0.003
<i>K. pneumoniae</i> CF1304	TEM-16	5.80	0.09	0.06
<i>K. pneumoniae</i> E264	TEM-17	10.36	0.66	0.004
<i>K. pneumoniae</i> CF1104	TEM-24	10.48	7.13	0.01
<i>E. coli</i> CF1609	TEM-25	2.58	0.04	0.02
<i>K. pneumoniae</i> 5657	TEM-26	0.56	0.08	0.02
<i>Serratia</i> S6	Sme-I	15.65	0.68	19.55

*All inhibitory values are determined against the chromogenic cephalosporin in a colorimetric assay.

5 In general, it can be concluded that Na-HMPAS is comparable to lithium clavulanate.

Susceptability assay for β -lactamase producing species *H. influenzae* and *M. catarrhalis*: The *in vitro* activity
10 of various ratios of 6- β -HMPAS and amoxicillin was assessed using clinical isolates of *H. influenzae* and *M. catarrhalis* that produce β -lactamase. The NCCLS (National Committee for Clinical Laboratory Standards) approved susceptibility method for Augmentin uses a
15 fixed 2:1 ratio of amoxicillin/clavulanate. The results indicated that for 46 beta-lactamase (+) strains of *H. influenzae*, the amoxicillin MIC₅₀ and MIC₉₀ values (i.e., the minimal inhibitory concentrations required to prevent the growth of either 50% or 90% of the isolates
20 tested) for both amoxicillin/clavulanate and amoxicillin/6- β -HMPAS were 1 and 2 μ g/ml, respectively, while the values for 2:1 amoxicillin/sulbactam were 4 and 8 μ g/ml. Note that the numbers refer to the amoxicillin concentration in the mixture.

25 For 48 isolates of *M. catarrhalis*, the MIC₅₀ and MIC₉₀ values for amoxicillin/clavulanate were ≤ 0.125 and 0.25 μ g/ml, and 0.5 and 1.0 μ g/ml for amoxicillin/6- β -HMPAS, respectively. Values for amoxicillin/sulbactam (2:1) were 0.25 and 1.0 μ g/ml. Thus, MICs obtained with
30 whole cells do not always correlate well with inhibitor potencies against cell-free beta-lactamases, as sulbactam was consistently more potent against the BRO-1/2 enzymes found in *M. catarrhalis*.

5 Susceptability assay for Non- β -lactamase producing
 species *Streptococcus pneumoniae*: The *in vitro* activity
 of the combination was compared with that observed with
 amoxicillin alone against clinical isolates of *S.*
 pneumoniae that were classified as penicillin-
10 susceptible, -intermediate and -resistant. Some of
 these strains showed high- level resistance to
 penicillin and amoxicillin with MICs in the 4-8 $\mu\text{g/ml}$
 range. As expected for a pathogen with PBP-based
 resistance, results for isolates of *S. pneumoniae*
15 confirmed that the presence of inhibitors had no
 influence on amoxicillin MICs.

 The amoxicillin MIC₅₀s and MIC₉₀s for 21 penicillin-
 resistant strains (penicillin MICs from 1-8 $\mu\text{g/ml}$) were
 2 and 4 $\mu\text{g/ml}$ for amoxicillin alone and for all beta-
20 lactamase inhibitor combinations tested at
 amoxicillin/inhibitor ratios of 2:1, 7:1 and 14:1.
 Finally, all combinations were tested against a group of
 21 penicillin-intermediate *S. pneumoniae* and 12
 penicillin-susceptible isolates. Again, all of the MICs
25 in both groups reflected the amoxicillin component of
 the combination. Amoxicillin MICs for the intermediate
 group ranged from 0.03 to 1 $\mu\text{g/ml}$ and the MICs for the
 susceptible group were ≤ 0.0156 to 0.06 $\mu\text{g/ml}$.

30 Assay Methodology: The assay was performed according to
 the method described in NCCLS Document M7-A4, December
 1997 and M100-S12, 2002, Methods for Dilution
 Antimicrobial Susceptibility Tests for Bacteria that
 Grow Aerobically- Approved Standard.

5 PREPARATION OF FROZEN STOCKS: *H. influenzae* are grown on chocolate agar plates. Colonies are suspended into Haemophilus test medium (HTM, Remel Diagnostics) which has been pH adjusted to 7.4 with 1N NaOH and filter sterilized. This is mixed with 50% glycerol to a
10 final concentration of 20% glycerol. Growth of *Streptococcus pneumoniae* and *Moraxella catarrhalis* is scraped off sheep blood agar plates and placed into Mueller Hinton broth plus 5% lysed sheep blood. For freezing, 50% glycerol is added to a final concentration
15 of 20%. All are frozen at -70 °C.

 PREPARATION OF DRUG PLATES: 96-well microtiter plates are used for the drug dilutions. All drugs are weighed out in sufficient quantity to make a 4X working stock solution. Drug is solubilized in DMSO or other
20 appropriate solvent, dissolved to volume in testing medium, and 100 µl is serially diluted twofold through a series of 10 drug wells each containing an initial volume of 100 µl medium [columns 1 through 10] and 1 drug well with no inoculum [column 11]. Column 12 is a
25 bacterial inoculum control well containing no drug. Final volume in each well is 100 µl.

 Drug plates for *H. influenzae* are serially diluted in HTM which has been pH adjusted to 7.4 with 1 N NaOH and filter sterilized. The other two species are
30 diluted in Mueller Hinton broth plus 5% lysed horse blood. Control compounds are run with each assay. Drug plates are frozen at --70 °C and thawed on the day of use.

 GROWTH OF INOCULUM: *H. influenzae* are grown
35 overnight on Mueller Hinton agar plates with 1%

5 hemoglobin and with 1% GCHI [chocolate agar plates] in a
5% CO₂ incubator overnight at 37 °C. *S. pneumoniae* and
M. catarrhalis are grown on Mueller Hinton agar
containing 5% sheep blood under the same conditions.

PREPARATION OF INOCULUM: Overnight growth from an
10 agar plate was taken and resuspended in the appropriate
test medium. All suspensions were adjusted to a
standard OD by spectrophotometry on the day of the assay
using Haemophilus test medium (HTM) broth for *H.*
influenzae or cation supplemented Mueller Hinton broth
15 plus 5% lysed horse blood (for *S. pneumoniae* and *M.*
catarrhalis) to a turbidity corresponding to a 0.5
McFarland standard suspension (about 1 to 2 x 10⁸
CFU/ml). This suspension had an OD₆₂₅ of 0.14. To
obtain a final inoculum of 2-7 x 10⁵ cfu/ml in the well
20 (final volume of 200 µl), the following dilutions were
made from the McFarland stock:

All *H. influenzae* strains were diluted 1/100 in
HTM.

All *S. pneumoniae* and *M. catarrhalis* were diluted
25 1:100 in cation supplemented Mueller Hinton broth
containing 5% lysed horse blood.

INOCULATION OF PLATES: 100 µl of the diluted
inoculum is added to each 100 µl of diluted drug in the
sterile test plate. Total volume for the test is 200 µl
30 per well. Strains that have been diluted appropriately
(see above) into microtiter wells will have a final
inoculum of 2 to 7 x 10⁵ CFU/ ml. These cell inocula are
confirmed on random plates by performing viability
counts of the wells at zero time. This is easily done
35 by removing 10 µl from the well and diluting it in 10 ml

5 of sterile, physiological saline (1:1000 dilution).
After vortexing, 100 µl of the diluted suspension is
spread on a blood agar plate or a chocolate agar plate
in the case of *H. influenzae*. Following incubation, the
presence of 50 colonies indicates an inoculum density of
10 5 x 10⁵ CFU/ml. Cultures used for inocula into the
microtiter trays are streaked for single colonies and
observed for typical colony morphology.

INCUBATION OF MICROTITER PLATES: After placing
plastic lids on the plates, microtiter plates are
15 incubated in plastic boxes in a controlled humidity
incubator to prevent evaporation from the wells. Plates
are stacked no more than 4 high. All microtiter plates
are incubated aerobically at 35 °C for 24 hours.

All plates are incubated and read after 24 hours
20 and results are recorded only if the control drugs for
the NCCLS type strain *H. influenzae* ATCC 49766 and *S.*
pneumoniae ATCC 49619 is within the published range
(NCCLS, M100-S12, 2002).

25 Example 13

In Vivo Efficacy

The *in vivo* β-lactamase inhibitory activity of 6-β-
HMPAS was determined for the β-lactamase (+) pathogens
that were evaluated in our pre-clinical infection
30 models. The data for these selected isolates indicated
that 6-β-HMPAS is generally equivalent to clavulanate
for β-lactamases from the respiratory pathogens *H.*
influenzae and *M. catarrhalis*.

Gerbil otitis media model: In this model, Mongolian
35 gerbils were challenged with *S. pneumoniae* or *H.*

5 *influenzae*. Female Mongolian gerbils (50-60 g) were challenged with log 5-6 CFU of *H. influenzae* or *S. pneumoniae* delivered in a 50 μ L volume into the left tympanic bulla. Eighteen hours post-challenge, a dose-response therapeutic regimen was initiated (t.i.d. for 2
10 days) with the combination of Amoxicillin and Prodrug 3 (7:1) delivering the dosage in a 500 μ L volume of 0.5% methylcellulose vehicle. ED50s were calculated from bacterial clearance data on day 4 post-challenge.

The amoxicillin/Prodrug 3 and Augmentin
15 combinations were equally effective in clearing this pathogen with ED₅₀s of 6-10 mg/kg, and outcomes for the 7:1 and 14:1 combinations were equivalent. Amoxicillin as a single agent failed against this pathogen.

Murine systemic infection model: In this model,
20 Female CF-1 or DBA/2 mice (18-20g) were challenged intraperitoneally with log 2-6 CFU of *S. pneumoniae*, *S. aureus* or *M. catarrhalis* suspended in broth, 10% mucin or 3% Brewers yeast, respectively, and delivered in a 500 μ L volume. One hour post-challenge, a dose-
25 response therapeutic regimen was initiated (b.i.d. for 1 day) with the combination of Amoxicillin/Prodrug 3 (7:1) delivering the dosage in a 200 μ L volume of 0.5% methylcellulose vehicle. ED50s were calculated from the survival data on day 4 post-challenge.

30 The combination of amoxicillin/Prodrug 3 was effective in protecting mice from death from all of these β -lactamase (+) strains. In general, the activity of the amoxicillin/Prodrug 3 combination was comparable to that of Augmentin (i.e. equivalent versus *H. influenzae* and slightly less against *M. catarrhalis*).
35

5 The 7:1 combinations were generally more effective than the 14:1 combinations. Data for the skin and skin structure pathogens *S. aureus*, *K. pneumoniae* and *E. coli* are also included in the following tables.

Murine pneumonia model: In this model, Female CF-1
10 (18-20g) were challenged intranasally with log 5-6 CFU of *S. pneumoniae* delivered in a 40 μ L volume and eighteen hours post-challenge, a dose-response therapeutic regimen was initiated (b.i.d. for 2 days) with the combination of Amoxicillin/Prodrug 3 (7:1)
15 delivering the dosage in a 200 μ L volume of 0.5% methylcellulose vehicle. ED50s were calculated from the survival data on day 10 post-challenge.

Amoxicillin, amoxicillin/Prodrug 3 and Augmentin were equally effective against a penicillin-tolerant
20 (PD₅₀s of 22-25 mg/kg) and penicillin-susceptible pneumococcal strain (PD₅₀s of 2.7-3.3 mg/kg). Since penicillin-tolerant strains of pneumococci do not harbor a β -lactamase, the activity of amoxicillin is not improved (nor is it antagonized) by the presence of 6- β -
25 HMPAS or clavulanate. The higher PD₅₀s noted with the penicillin-tolerant strain relative to the penicillin-susceptible strain is consistent with the higher MIC.

In summary, the *in vivo* oral activity for the combination of amoxicillin/Prodrug 3 (7:1 and 14:1) was
30 compared in a head-to-head fashion with Augmentin in a gerbil otitis media model and mouse models of peritonitis and pneumonia. The amoxicillin/Prodrug 3 combination demonstrated comparable *in vivo* activity to that of Augmentin vs. respiratory tract pathogens (*H.*
35 *influenzae*, *M. catarrhalis* and *S. pneumoniae*) and skin

5 and soft tissue pathogens (*S. aureus*, *E. coli* and *K. pneumoniae*) in these models. The *in vivo* performance of the amoxicillin/Prodrug 3 was consistent with the *in vitro* activity of this combination when assayed at a 2:1 ratio in the MIC assay.

10 In Vivo Antibacterial Activity (Oral) vs. Respiratory Tract and Skin & Skin Structure Pathogens (ED50, mg/kg)

Pathogen	Amoxicillin	Prodrug 3	Amoxicillin/Prodrug 3 (7/1 ratio)	Augmentin (7/1 ratio)
Gerbil Otitis Media Model				
<i>Haemophilus influenzae</i> (54A1218) ²	>50	>25	8.9/1.3 ¹	9.9/1.4
Murine Systemic Model				
<i>Haemophilus influenzae</i> (54A1218)	>100	>25	9.8/1.4	13.4/1.9
<i>Moraxella catarrhalis</i> (87A1115)	>100	>100	37.6/5.4	12.6/1.8
<i>Staphylococcus aureus</i> (01A0400)	>100	>12.5	30.6/4.4	17.8/2.5
<i>Klebsiella pneumoniae</i> (53A0031)	>200	>25	20.2/2.9	13.0/1.8
<i>Escherichia coli</i> (51A0257)	>200	>100	62.2/8.9	146/20.8
Mouse Pneumonia Model				
<i>Streptococcus pneumoniae</i> (02J1095)	25	>25	21.8/3.1	21.8/3.1
<i>Streptococcus pneumoniae</i> (02J1016)	3.3	>25	2.66/0.38	2.66/0.38

¹The first value indicates the amoxicillin concentration while the second value is the beta-lactamase inhibitor.

15 ²Numbers in parantheses indicate Pfizer strain ID numbers.

5 In Vivo Antibacterial Activity (Oral) vs. Respiratory Tract and Skin & Skin Structure Pathogens (ED50, mg/kg)

Pathogen	Amoxicillin	Prodrug 3	Amoxicillin/Prodrug 3 (14/1 ratio)	Augmentin (14/1 ratio)
Gerbil Otitis Media Model				
<i>Haemophilus influenzae</i> (54A1218)	>50	>25	10.5/0.73 ¹	5.8/0.4
Murine Systemic Model				
<i>Haemophilus influenzae</i> (54A1218)	>100	>25	12.3/0.88	37.9/2.7
<i>Moraxella catarrhalis</i> (87A1115)	>100	>100	42.5/3.0	23.6/1.7
<i>Staphylococcus aureus</i> (01A0400)	>100	>12.5	94.2/6.7	24.4/1.7
<i>Klebsiella pneumoniae</i> (53A0031)	>200	>25	23.4/1.7	23.4/1.7
<i>Escherichia coli</i> (51A0257)	>200	>100	134/9.6	196/14
Mouse Pneumonia Model				
<i>Streptococcus pneumoniae</i> (02J1095)	25	>25	23.6/1.7	17.8/1.3
<i>Streptococcus pneumoniae</i> (02J1016)	3.3	>25	1.6/0.11	1.8/0.12

¹The first value indicates the amoxicillin concentration while the second value is the beta-lactamase inhibitor.

²Numbers in parantheses indicate Pfizer strain ID

10 numbers.